View Item 

Show simple item record

Factors Influencing the Magnitude and Clinical Significance of Drug Interactions Between Azole Antifungals and Select Immunosuppressants
dc.contributor.authorSaad, Aline H.en_US
dc.contributor.authorDePestel, Daryl D.en_US
dc.contributor.authorCarver, Peggy L.en_US
dc.date.accessioned2012-03-16T15:56:18Z
dc.date.available2012-03-16T15:56:18Z
dc.date.issued2006-12en_US
dc.identifier.citationSaad, Aline H.; DePestel, Daryl D.; Carver, Peggy L. (2006). "Factors Influencing the Magnitude and Clinical Significance of Drug Interactions Between Azole Antifungals and Select Immunosuppressants." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 26(12). <http://hdl.handle.net/2027.42/90188>en_US
dc.identifier.issn0277-0008en_US
dc.identifier.issn1875-9114en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/90188
dc.publisherBlackwell Publishing Ltden_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherSirolimusen_US
dc.subject.otherTacrolimusen_US
dc.subject.otherDrug Interactionsen_US
dc.subject.otherAzole Antifungalsen_US
dc.subject.otherImmunosuppressantsen_US
dc.subject.otherKetoconazoleen_US
dc.subject.otherItraconazoleen_US
dc.subject.otherFluconazoleen_US
dc.subject.otherVoriconazoleen_US
dc.subject.otherCyclosporineen_US
dc.titleFactors Influencing the Magnitude and Clinical Significance of Drug Interactions Between Azole Antifungals and Select Immunosuppressantsen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Pharmacy Services, University of Michigan Health System, Ann Arbor, Michigan and the Department of Clinical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan (all authors).en_US
dc.identifier.pmid17125435en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/90188/1/phco.26.12.1730.pdf
dc.identifier.doi10.1592/phco.26.12.1730en_US
dc.identifier.sourcePharmacotherapy: The Journal of Human Pharmacology and Drug Therapyen_US
dc.identifier.citedreferenceBanerjee R., Leaver N., Lyster H., Banner NR. Coadministration of itraconazole and tacrolimus after thoracic organ transplantation. Transplant Proc 2001; 33: 1600 – 2.en_US
dc.identifier.citedreferenceToda F., Tanabe K., Ito S., et al. Tacrolimus trough level adjustment after administration of fluconazole to kidney recipients. Transplant Proc 2002; 34: 1733 – 5.en_US
dc.identifier.citedreferenceHairhara Y., Makuuchi M., Kawarasaki H., et al. Effect of fluconazole on blood levels of tacrolimus [abstr]. Transplant Proc 1999; 31: 2767.en_US
dc.identifier.citedreferenceCapone D., Gentile A., Imperatore P., Palmiero G., Basile V.. Effects of itraconazole on tacrolimus blood concentrations in a renal transplant recipient. Ann Pharmacother 1999; 33: 1124 – 5.en_US
dc.identifier.citedreferenceBillaud EM, Guillemain R., Tacco F., Chevalier P.. Evidence for a pharmacokinetic interaction between itraconazole and tacrolimus in organ transplant patients. Br J Clin Pharmacol 1998; 46: 271 – 2.en_US
dc.identifier.citedreferenceWood N., Tan KKC, Allan R., Fielding A., Nichols DJ. Effect of voriconazole on the pharmacokinetics of tacrolimus [abstr]. In: Abstracts of the 41st interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, December 16–19, 2001. Washington, DC: American Society for Microbiology, 2001: A20.en_US
dc.identifier.citedreferenceZimmeran JJ, Gurr JA, DiLea C.. Study of the potential pharmacokinetic interaction between sirolimus (Rapamune) and ketoconazole: final report (protocol 0468E1–136‐US), vol 163/2. Wyeth‐Ayerst GMR‐31057, 1998.en_US
dc.identifier.citedreferenceThomas PP, Manivannan J., John GT, Jacob CK. Sirolimus and ketoconazole co‐prescription in renal transplant recipients. Transplantation 2004; 77: 474 – 5.en_US
dc.identifier.citedreferenceCervelli MJ. Fluconazole‐sirolimus drug interaction. Transplantation 2002; 74: 1477 – 8.en_US
dc.identifier.citedreferenceMarty FM, Lowry CM, Cutler CS, et al. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12 ( 5 ): 552 – 9.en_US
dc.identifier.citedreferenceGomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF, Benet LZ. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 1995; 58: 15 – 19.en_US
dc.identifier.citedreferenceOsowski CL, Dix SP, Lin LS, Mullins RE, Geller RB, Wingard JR. Evaluation of the drug interaction between intravenous high‐dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. Transplantation 1996; 61: 1268 – 72.en_US
dc.identifier.citedreferenceFloren LC, Bekersky I., Benet LZ, et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 1997; 62: 41 – 9.en_US
dc.identifier.citedreferenceManez R., Martin M., Raman V., et al. Fluconazole therapy in transplant recipients receiving FK 506. Transplantation 1994; 57: 1521 – 3.en_US
dc.identifier.citedreferenceTuteja S., Alloway RR, Johnson JA, Gaber AO. The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. Transplantation 2001; 71: 1303 – 7.en_US
dc.identifier.citedreferenceTaro Pharmaceuticals. Ketoconazole package insert. Hawthorne, NY; 1999.en_US
dc.identifier.citedreferencePfizer Roerig. Diflucan (fluconazole) package insert. New York, NY; 2004.en_US
dc.identifier.citedreferenceJanssen Pharmaceutica Products. Sporanox (itraconazole) package insert. Titusville, NJ; 2002.en_US
dc.identifier.citedreferenceFitzsimmons WE, Bekersky I., Dressler D., Raye K., Hodosh E., Mekki Q.. Demographic considerations in tacrolimus pharmacokinetics. Transplant Proc 1998; 30: 1359 – 64.en_US
dc.identifier.citedreferenceFirst MR, Schroeder TJ, Daoud J., et al. Ketoconazole is not associated with increased inpatient or outpatient resources while decreasing cyclosporine annual costs by approximately $3,300 per patient. Presented at the 16th annual meeting of the American Society of Transplant Physicians, Dallas, TX, May 1114, 1997.en_US
dc.identifier.citedreferenceMartin JE, Daoud AJ, Schroeder TJ, First MR. The clinical and economic potential of cyclosporin drug interactions. Pharmacoeconomics 1999; 15: 317 – 37.en_US
dc.identifier.citedreferenceEl‐Agroudy AE, Sobh MA, Hamdy AF, Ghoneim MA. A prospective, randomized study of coadministration of ketoconazole and cyclosporine in kidney transplant recipients: ten‐year follow‐up. Transplantation 2004; 77: 1371 – 6.en_US
dc.identifier.citedreferenceDominguez J., Kompatzki A., Foradori A., Norambuena R.. Ketoconazole alters cyclosporine pharmacokinetic profile and may predispose to acute rejection. Transplant Proc 2003; 35: 2522 – 3.en_US
dc.identifier.citedreferenceRossi SJ, Martin JE, Gelhot A., et al. A randomized prospective trial of fluconazole vs. clotrimazole for fungal prophylaxis in liver transplant recipients. Presented at the 14th annual meeting of the American Society of Transplant Physicians, Chicago, IL, May 1415, 1995.en_US
dc.identifier.citedreferenceEl‐Dahshan KF, Bakr MA, Donia AF, Badr Ael S., Sobh MA. Co‐administration of ketoconazole to tacrolimus‐treated kidney transplant recipients: a prospective randomized study. Nephrol Dial Transplant 2004; 19: 1613 – 17.en_US
dc.identifier.citedreferenceKirchner GI, Meier‐Wiedenbach I., Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004; 43: 83 – 95.en_US
dc.identifier.citedreferenceKovarik JM, Beyer D., Bizot MN, Jiang Q., Shenouda M., Schmouder RL. Blood concentrations of everolimus are markedly increased by ketoconazole. J Clin Pharmacol 2005; 45: 514 – 18.en_US
dc.identifier.citedreferenceMcNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980–1997. Clin Infect Dis 2001; 33: 641 – 7.en_US
dc.identifier.citedreferenceKontoyiannis DP, Mantadakis E., Samonis G.. Systemic mycoses in the immunocompromised host: an update in antifungal therapy. J Hosp Infect 2003; 53: 243 – 58.en_US
dc.identifier.citedreferenceRubin RH. Overview: pathogenesis of fungal infections in the organ transplant recipient. Transpl Infect Dis 2002; 4 ( suppl 3 ): 12 – 17.en_US
dc.identifier.citedreferenceLin SJ, Schranz J., Teutsch SM. Aspergillosis case‐fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32 ( 3 ): 358 – 66.en_US
dc.identifier.citedreferenceFung JJ. Fungal infection in liver transplantation. Transpl Infect Dis 2002; 4 ( suppl 3 ): 18 – 23.en_US
dc.identifier.citedreferenceFishman JA. Overview: fungal infections in the transplant patient. Transpl Infect Dis 2002; 4 ( suppl 3 ): 3 – 11.en_US
dc.identifier.citedreferenceSingh N.. Treatment of opportunistic mycoses: how long is long enough? Lancet Infect Dis 2003; 3: 703 – 8.en_US
dc.identifier.citedreferenceRubin RH, Ikonen T., Gummert JF, Morris RE. The therapeutic prescription for the organ transplant recipient: the linkage of immunosuppression and antimicrobial strategies. Transpl Infect Dis 1999; 1: 29 – 39.en_US
dc.identifier.citedreferenceAlbengres E., Le Louet H., Tillement JP. Systemic antifungal agents. Drug interactions of clinical significance. Drug Saf 1998; 18: 83 – 97.en_US
dc.identifier.citedreferenceBates DW, Yu DT. Clinical impact of drug‐drug interactions with systemic azole antifungals. Drugs Today (Barc) 2003; 39: 801 – 13.en_US
dc.identifier.citedreferenceKatz HI. Drug interactions of the newer oral antifungal agents. Br J Dermatol 1999; 141 ( suppl 56 ): 26 – 32.en_US
dc.identifier.citedreferenceVenkatakrishnan K., von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000; 38: 111 – 80.en_US
dc.identifier.citedreferenceGillum JG, Israel DS, Polk RE. Pharmacokinetic drug interactions with antimicrobial agents. Clin Pharmacokinet 1993; 25: 450 – 82.en_US
dc.identifier.citedreferenceVenkatakrishnan K., Von Moltke LL, Greenblatt DJ. Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J Clin Pharmacol 2001; 41: 1149 – 79.en_US
dc.identifier.citedreferenceZhang Y., Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P‐glycoprotein. Clin Pharmacokinet 2001; 40: 159 – 68.en_US
dc.identifier.citedreferenceDavidson MH. Does differing metabolism by cytochrome P450 have clinical importance? Curr Atheroscler Rep 2000; 2: 14 – 19.en_US
dc.identifier.citedreferenceDresser GK, Spence JD, Bailey DG. Pharmacokinetic‐pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38: 41 – 57.en_US
dc.identifier.citedreferenceHall SD, Thummel KE, Watkins PB, et al. Molecular and physical mechanisms of first‐pass extraction. Drug Metab Dispos 1999; 27: 161 – 6.en_US
dc.identifier.citedreferenceLin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998; 35: 361 – 90.en_US
dc.identifier.citedreferenceApseloff G., Hilligoss DM, Gardner MJ, et al. Induction of fluconazole metabolism by rifampin: in vivo study in humans. J Clin Pharmacol 1991; 31: 358 – 61.en_US
dc.identifier.citedreferenceTucker WS Jr, Snell BB, Island DP, Gregg CR. Reversible adrenal insufficiency induced by ketoconazole. JAMA 1985; 253: 2413 – 14.en_US
dc.identifier.citedreferenceChristians U., Strom T., Zhang YL, et al. Active drug transport of immunosuppressants: new insights for pharmacokinetics and pharmacodynamics. Ther Drug Monit 2006; 28 ( 1 ): 39 – 44.en_US
dc.identifier.citedreferenceVenkataramanan R., Zang S., Gayowski T., Singh N.. Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. Antimicrob Agents Chemother 2002; 46: 3091 – 3.en_US
dc.identifier.citedreferenceSansone A., Belle D., Statkevich P., et al. Effect of posaconazole on the pharmacokinetics of tacrolimus in healthy volunteers [abstr]. In: Abstracts of the 43rd interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, September 14–17, 2003. Washington, DC: American Society for Microbiology, 2003: 1603.en_US
dc.identifier.citedreferenceCourtney RD, Statkevich P., Laughlin M., et al. Effect of posaconazole on the pharmacokinetics of cyclosporine [abstr]. In: Abstracts of the 41st interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, December 16–19, 2001. Washington, DC: American Society for Microbiology, 2001: A27.en_US
dc.identifier.citedreferenceLo A., Burckart GJ. P—glycoprotein and drug therapy in organ transplantation. J Clin Pharmacol 1999; 39: 995 – 1005.en_US
dc.identifier.citedreferenceBenet LZ, Cummins CL, Wu CY. Transporter‐enzyme interactions: implications for predicting drug‐drug interactions from in vitro data. Curr Drug Metab 2003; 4: 393 – 8.en_US
dc.identifier.citedreferenceChristians U., Jacobsen W., Benet LZ, Lampen A.. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 2002; 41: 813 – 51.en_US
dc.identifier.citedreferenceWang EJ, Lew K., Casciano CN, Clement RP, Johnson WW. Interaction of common azole antifungals with P glycoprotein. Antimicrob Agents Chemother 2002; 46: 160 – 5.en_US
dc.identifier.citedreferenceBertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997; 32: 210 – 58.en_US
dc.identifier.citedreferenceThummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998; 38: 389 – 430.en_US
dc.identifier.citedreferenceMcConn DJ II, Lin YS, Allen K., Kunze KL, Thummel KE. Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite‐inhibitor complex‐forming drugs. Drug Metab Dispos 2004; 32: 1083 – 91.en_US
dc.identifier.citedreferenceGibbs MA, Thummel KE, Shen DD, Kunze KL. Inhibition of cytochrome P‐450 3A (CYP3A) in human intestinal and liver microsomes: comparison of K i values and impact of CYP3A5 expression. Drug Metab Dispos 1999; 27: 180 – 7.en_US
dc.identifier.citedreferenceBachmann KA, Lewis JD. Predicting inhibitory drug‐drug interactions and evaluating drug interaction reports using inhibition constants. Ann Pharmacother 2005; 39: 1064 – 72.en_US
dc.identifier.citedreferenceNeal JM, Kunze KL, Levy RH, O'Reilly RA, Trager WF. Kiiv, an in vivo parameter for predicting the magnitude of a drug interaction arising from competitive enzyme inhibition. Drug Metab Dispos 2003; 31: 1043 – 8.en_US
dc.identifier.citedreferenceMaertens JA. History of the development of azole derivatives. Clin Microbiol Infect 2004; 10 ( suppl 1 ): 1 – 10.en_US
dc.identifier.citedreferenceHalloran PF, Gourishankar S.. Principles and overview of immunosuppression. In: Norman DJ, Turka LA, eds. Primer on transplantation, 2nd ed.. Mt. Laurel, NJ: American Society of Transplantation, 2001: 87 – 97.en_US
dc.identifier.citedreferenceIsoherranen N., Kunze KL, Allen KE, Nelson WL, Thummel KE. Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Dispos 2004; 32: 1121 – 31.en_US
dc.identifier.citedreferenceGubbins PO, Amsden JR. Drug‐drug interactions of antifungal agents and implications for patient care. Expert Opin Pharmacother 2005; 6: 2231 – 43.en_US
dc.identifier.citedreferencePfizer Inc. Vfend (voriconazole) package insert. New York, NY; 2003.en_US
dc.identifier.citedreferencePearson MM, Rogers PD, Cleary JD, Chapman SW. Voriconazole: a new triazole antifungal agent. Ann Pharmacother 2003; 37: 420 – 32.en_US
dc.identifier.citedreferenceGhosal A., Hapangama N., Yuan Y., et al. Identification of human UDP‐glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Drug Metab Dispos 2004; 32: 267 – 71.en_US
dc.identifier.citedreferenceSlain D., Rogers PD, Cleary JD, Chapman SW. Intravenous itraconazole. Ann Pharmacother 2001; 35: 720 – 9.en_US
dc.identifier.citedreferenceOmar G., Whiting PH, Hawksworth GM, Humphrey MJ, Burke MD. Ketoconazole and fluconazole inhibition of the metabolism of cyclosporin A by human liver in vitro. Ther Drug Monit 1997; 19: 436 – 45.en_US
dc.identifier.citedreferenceWexler D., Courtney R., Richards W., Banfield C., Lim J., Laughlin M.. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open‐label, two‐way crossover study. Eur J Pharm Sci 2004; 21: 645 – 53.en_US
dc.identifier.citedreferenceGaston RS. Maintenance immunosuppression in the renal transplant recipient: an overview. Am J Kidney Dis 2001; 38: S25 – 35.en_US
dc.identifier.citedreferenceMahalati K., Kahan BD. Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet 2001; 40: 573 – 85.en_US
dc.identifier.citedreferenceDunn CJ, Wagstaff AJ, Perry CM, Plosker GL, Goa KL. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion‐based formulation (Neoral) 1 in organ transplantation. Drugs 2001; 61: 1957 – 2016.en_US
dc.identifier.citedreferenceAbraham MA, Thomas PP, John GT, Job V., Shankar V., Jacob CK. Efficacy and safety of low‐dose ketoconazole (50 mg) to reduce the cost of cyclosporine in renal allograft recipients. Transplant Proc 2003; 35: 215 – 16.en_US
dc.identifier.citedreferenceLomaestro BM, Piatek MA. Update on drug interactions with azole antifungal agents. Ann Pharmacother 1998; 32: 915 – 28.en_US
dc.identifier.citedreferenceCanafax DM, Graves NM, Hilligoss DM, Carleton BC, Gardner MJ, Matas AJ. Interaction between cyclosporine and fluconazole in renal allograft recipients. Transplantation 1991; 51 ( 5 ): 1014 – 18.en_US
dc.identifier.citedreferenceRomero AJ, Pogamp PL, Nilsson LG, Wood N.. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther 2002; 71: 226 – 34.en_US
dc.identifier.citedreferenceMoreno M., Latorre A., Manzanares C., et al. Clinical management of tacrolimus drug interactions in renal transplant patients. Transplant Proc 1999; 31: 2252 – 3.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
phco.26.12.1730.pdf
Size:
101.6KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.